Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

NICE recommends Rozlytrek (entrectinib) as treatment for NSCLC

europeanpharmaceuticalreviewJune 17, 2020

Tag: NICE , Rozlytrek , NSCLC

PharmaSources Customer Service